Stem cell therapy specialist Reneuron PLC (LON:RENE) is making good progress on all of its clinical trial candidates and also in the lab, chief executive Olav Hellebo said today.
"Our therapeutic development programmes have continued to progress well during the period, the highlight being positive Phase II data from the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability.“
WATCH: It's 'all systems go' as ReNeuron gears up for Phase III stroke disability study
“We are encouraged by the subsequent feedback we have received from the FDA regarding our planned US pivotal Phase III clinical trial with CTX for stroke disability.
“The unmet medical need in chronic stroke disability is enormous and we are ever closer to being able to offer a potential new therapeutic option to these patients.
"We have made significant advances with our hRPC cell therapy candidate, both in terms of progressing the ongoing US Phase I/II clinical trial in retinitis pigmentosa and obtaining FDA approval for the cryopreserved formulation of this therapeutic candidate, enabling us to expand our ophthalmology programmes into new indications.
He added the pre-clinic ExoPr0 exosome therapy candidate targeting cancer had also progressed well.
"With our stroke programme moving into Phase III clinical development over the coming months and our retinal disease programmes moving into Phase II clinical development later this year, we expect to achieve significant clinical milestones during each of the next three years."
Reneuron posted a loss of £15.6mln (£11.4mln); with a cash burn over the year of £12.6mln. Cash equivalents at the year end were £53mln (2016: £65.7mln).